bacterial infectious disease News
-
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT. A live webcast of the presentation can be accessed through the ...
-
Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT. A live webcast of the ...
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET. A live webcast of the presentation can be ...
-
Vaxcyte to Participate in Upcoming Investor Conferences in May
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: BofA Securities 2022 Healthcare Conference May 10-13, 2022; Las Vegas, NV Fireside chat will ...
-
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed ...
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to ...
-
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary ...
-
XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report that it has signed a non-binding Letter of Intent (“LOI”) to identify and assess potential business synergies for manufacturing, import/export, distribution and product development with a US-based thin film manufacturing firm (the “Firm”). ...
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to ...
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today ...
-
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase 1 and 2 Portions of the VAX-24 Phase 1/2 Study Expected by the End of 2022 Initiation of ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná (IBMP) in Brazil. IBMP is a ...
-
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which ...
-
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major ...
-
NanoPin Technologies Founder`s Study Demonstrates Greater Accuracy in Detecting TB in Infants
NanoPin Technologies Inc, a biotechnology company focused on developing advanced diagnostics to improve the lives of millions of individuals affected by infectious diseases worldwide, announced the release of a scientific study conducted by founder Tony Hu, Ph.D. Dr. Hu is a professor and Weatherhead Presidential Chair in Biotechnology Innovation at the Tulane University School of Medicine. ...
-
XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you